VASCEPA (icosapent ethyl) is a prescription medication used to reduce the risk of cardiovascular events in certain adult patients. According to the FDA, VASCEPA is indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride levels (≥150 mg/dL) and established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease [2].
As per the drug patent watch website, the patent for VASCEPA is set to expire on September 28, 2030 [1]. However, the duration of taking VASCEPA and statins together is dependent on the individual's medical condition and the recommendation of their healthcare provider. The duration of therapy may vary depending on the patient's response to treatment and the risk of cardiovascular events.
According to the VASCEPA prescribing information, the recommended dosage of VASCEPA is 4 grams per day. The medication can be taken with or without food. The dosage of statins should be individualized based on the patient's baseline lipid levels, cardiovascular risk, and response to therapy. The VASCEPA prescribing information does not provide specific guidance on the duration of therapy [3].
In conclusion, the duration of taking VASCEPA and statins together should be determined by the individual's medical condition and the recommendation of their healthcare provider. The VASCEPA prescribing information does not provide specific guidance on the duration of therapy. It is essential to follow the healthcare provider's instructions regarding the duration of therapy and to attend regular follow-up appointments to monitor the response to treatment and assess the need for continued therapy.
Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.fda.gov/news-events/press-announcements/fda-approves-use-drug-reduce-risk-cardiovascular-events-certain-adult-patient-groups
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202057s035lbl.pdf